STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on May 9, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").
As previously reported, the Company was notified on December 1, 2023, that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid of the Company's ordinary shares needed to be at least $1.00 for a minimum of 10 consecutive business days.
The Notification Letter confirmed that the Company evidenced a closing bid price at or greater than the $1.00 per ordinary share minimum requirement for 10 consecutive business days from April 25, 2024, to May 8, 2024, and that the Company has regained compliance with the Minimum Bid Price Requirement.
紐約州石溪/ACCESSWIRE/2024年5月10日/基於PCR的DNA技術的領導者Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA)今天宣佈,它於2024年5月9日收到了納斯達克股票市場(“納斯達克”)上市資格部門的通知信(“通知信”),通知該公司已恢復遵守規定的最低出價要求在《納斯達克上市規則》第5550(a)(2)(“最低出價要求”)中。
正如先前報道的那樣,該公司於2023年12月1日接到通知,其普通股未能按照最低出價要求的要求,在過去的連續30個工作日內將最低出價維持在1.00美元。爲了重新遵守最低出價要求,公司普通股的收盤價必須至少爲1.00美元,至少連續10個工作日。
通知信證實,從2024年4月25日至2024年5月8日,公司連續10個工作日證明收盤價等於或高於每股普通股最低1.00美元,並且公司已恢復遵守最低出價要求。